Relapsing Remitting Multiple Sclerosis News and Research

RSS
Daclizumab HYP superior to interferon in relapsing–remitting MS

Daclizumab HYP superior to interferon in relapsing–remitting MS

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Quitting smoking may delay secondary progressive MS onset

Quitting smoking may delay secondary progressive MS onset

Mental visual imagery training may improve AM/EFT functioning in RR-MS patients

Mental visual imagery training may improve AM/EFT functioning in RR-MS patients

Shorter washout period during transition from natalizumab supported

Shorter washout period during transition from natalizumab supported

New longer-term data on Genzyme's relapsing MS treatments to be presented at AAN 2015

New longer-term data on Genzyme's relapsing MS treatments to be presented at AAN 2015

University of Cambridge's Alastair Compston wins 2015 John Dystel Prize for MS Research

University of Cambridge's Alastair Compston wins 2015 John Dystel Prize for MS Research

Promising results for stem cell therapy in MS

Promising results for stem cell therapy in MS

Study: Stem cell transplantation improves quality of life in patients with relapsing-remitting MS

Study: Stem cell transplantation improves quality of life in patients with relapsing-remitting MS

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Dimethyl fumarate offers no added benefits for adults with RRMS

Dimethyl fumarate offers no added benefits for adults with RRMS

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Study: People with mobility impairments under age 65 have higher rates of smoking

Study: People with mobility impairments under age 65 have higher rates of smoking

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Merck Serono launches web-based software system for MS patients receiving Rebif treatment

Merck Serono launches web-based software system for MS patients receiving Rebif treatment

Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent